Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH 2013: Emergent's otlertuzumab maintains ORR lead in Phase II

This article was originally published in Scrip

Executive Summary

Updated Phase II results for otlertuzumab from Emergent BioSolutions plus Teva Pharmaceutical's Treanda (bendamustine), which were presented at the American Society of Hematologists (ASH) Annual Meeting on 8 December, show that the CD37-targeting monoclonal antibody is maintaining its lead over Treanda alone.

Topics

Related Companies

UsernamePublicRestriction

Register

SC023720

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel